Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C34H43N3O3S2 |
| Molecular Weight | 605.854 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC(CCC)C1=CC=C(OCC2=CC=C(C=C2)C3=CSC(CN(CC(O)=O)CC4=NC=C(S4)C(C)(C)C)=N3)C=C1
InChI
InChIKey=FKGBFRNVTCFMGU-UHFFFAOYSA-N
InChI=1S/C34H43N3O3S2/c1-6-8-25(9-7-2)26-14-16-28(17-15-26)40-22-24-10-12-27(13-11-24)29-23-41-32(36-29)20-37(21-33(38)39)19-31-35-18-30(42-31)34(3,4)5/h10-18,23,25H,6-9,19-22H2,1-5H3,(H,38,39)
| Molecular Formula | C34H43N3O3S2 |
| Molecular Weight | 605.854 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:36:04 GMT 2023
by
admin
on
Sat Dec 16 11:36:04 GMT 2023
|
| Record UNII |
VH3F3DR5X3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
VH3F3DR5X3
Created by
admin on Sat Dec 16 11:36:04 GMT 2023 , Edited by admin on Sat Dec 16 11:36:04 GMT 2023
|
PRIMARY | |||
|
776309-04-7
Created by
admin on Sat Dec 16 11:36:04 GMT 2023 , Edited by admin on Sat Dec 16 11:36:04 GMT 2023
|
PRIMARY | |||
|
23080446
Created by
admin on Sat Dec 16 11:36:04 GMT 2023 , Edited by admin on Sat Dec 16 11:36:04 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antihyperglycaemic; Mechanism of Action: Protein-tyrosine-phosphatase inhibitor; Highest Development Phase: Discontinued for Type 2 diabetes mellitus; Most Recent Events: 09 Aug 2007 Discontinued - Phase-I for Type-2 diabetes mellitus (PO),09 Aug 2007 Discontinued - Phase-I for Type-2 diabetes mellitus in Japan (PO), 31 Oct 2006 Phase-I clinical trials in Type-2 diabetes mellitus (PO)
|
||
|
ACTIVE MOIETY |
Protein tyrosine phosphatase 1B (PTP1B), a negative regulator of insulin signalling, is a novel therapeutic target for type 2 diabetes mellitus. JTT-551 showed an inhibitory effect on PTP1B with a Ki value of 0.22 microM, and a mixed-type inhibition mode. Ki values of TCPTP, CD45 and LAR were 9.3, 30 or higher and 30 or higher microM, respectively, and JTT-551 exhibited clear selectivity against the other PTPs. Moreover, JTT-551 increased the insulin-stimulated glucose uptake in L6 cells. A single administration of JTT-551 in ob/ob mice enhanced the IR phosphorylation of liver and reduced the glucose level. In db/db mice, chronic administration showed a hypoglycaemic effect without an acceleration of body weight gain. JTT-551, a newly developed PTP1B inhibitor, improves glucose metabolism by enhancement of insulin signalling and could be useful in the treatment of type 2 diabetes mellitus.
|
||
|
ACTIVE MOIETY |
Protein tyrosine phosphatase 1B (PTP1B) is a negative regulator of leptin signaling as well as insulin signaling. JTT-551 is a new PTP1B inhibitor, which is reported to improve glucose metabolism by enhancement of insulin signaling. We have evaluated an antiobesity effect of JTT-551 using diet-induced obesity (DIO) mice. A single administration of JTT-551 was provided to DIO mice with or without leptin, and DIO mice were given food containing JTT-551 for six weeks. A single administration of JTT-551 with leptin treatment enhanced the food inhibition and the signal transducer and activator of transcription 3 (STAT3) phosphorylation in hypothalamus. Moreover, chronic administration of JTT-551 showed an antiobesity effect and an improvement of glucose and lipid metabolism in DIO mice.
|
